摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(tert-butyl)-2,5-dimethylpyridine

中文名称
——
中文别名
——
英文名称
3-(tert-butyl)-2,5-dimethylpyridine
英文别名
3-Tert-butyl-2,5-dimethylpyridine;3-tert-butyl-2,5-dimethylpyridine
3-(tert-butyl)-2,5-dimethylpyridine化学式
CAS
——
化学式
C11H17N
mdl
——
分子量
163.263
InChiKey
VJESMUKSQGXQDB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    4,4-二甲基-2-戊炔2-甲基烯丙基胺六氟磷酸钾 、 [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2 、 copper diacetate 作用下, 以 2-甲基-2-丁醇 为溶剂, 反应 0.25h, 以4%的产率得到3-(tert-butyl)-2,5-dimethylpyridine
    参考文献:
    名称:
    钌催化伯胺与内部炔烃通过C的氧化偶联。氢键活化:范围和机理研究
    摘要:
    Ru配合物催化伯胺与内部炔烃的氧化偶联是一种通用的原子经济学方法,在N杂环的合成中具有广泛的应用范围。反应通过微波辐射在15分钟内或在常规加热条件下的24小时内通过区域选择性CH键活化而进行。2,3,5-取代的吡啶,苯并[ h ]异喹啉,苯并[ g ]异喹啉,8,9-二氢-苯并[ de ]喹啉,5​​,6,7,8-四氢异喹啉,吡啶基[3, 4克]异喹啉和吡啶[4,3克取决于所用的起始伯胺,可以达到]异喹啉。在苄胺底物上的DFT计算支持了一种反应机理,该机理包括乙酸盐辅助的CH键活化,迁移插入和CN键形成步骤,涉及28–30 kcal mol -1。计算研究扩展到其他底物,即1-萘甲基,2-甲基烯丙基和2-噻吩甲胺。
    DOI:
    10.1002/chem.201500338
点击查看最新优质反应信息

文献信息

  • PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS
    申请人:MITSUI CHEMICALS AGRO, INC.
    公开号:US20200045968A1
    公开(公告)日:2020-02-13
    Pyridine compounds of Formula (1) are provided: wherein R1, R2, X, Y and Het are defined. The pyridine compounds can be used to treat or prevent plant diseases.
    提供了化合物的化学式(1):其中R1、R2、X、Y和Het均已定义。这些吡啶化合物可用于治疗或预防植物疾病。
  • [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS P2X7 MODULATORS
    申请人:Janssen Pharmaceutica NV
    公开号:US20150290190A1
    公开(公告)日:2015-10-15
    The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    本发明涉及一种化合物(I)及包含化合物(I)的药物组合物。本发明还涉及制备和使用化合物(I)的方法。
  • P2X7 MODULATORS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US20160016962A1
    公开(公告)日:2016-01-21
    The present invention is directed to a compound of Formula (I) Formula (I) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) and methods comprising administering to a subject at least one compound selected from compounds of Formula (I) for treating diseases mediated by P2X7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, Parkinson's disease, schizophrenia, Alzheimer's disease, Huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, Crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, Polycystic Kidney Disease, Glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, Amyotrophic Lateral Sclerosis, Chaga's Disease, chlamydia , neuroblastoma, Tuberculosis, and migraine.
    本发明涉及一种式(I)的化合物。本发明还涉及包含式(I)的化合物的制药组合物和方法,该方法包括向受体中注射至少一种从式(I)的化合物中选择的化合物,用于治疗由P2X7受体活性介导的疾病,例如类风湿性关节炎、骨关节炎、牛皮癣、脓毒症休克、过敏性皮炎、哮喘、过敏性哮喘、轻度至重度哮喘、类固醇耐受性哮喘、特发性肺纤维化、过敏性鼻炎、慢性阻塞性肺疾病、气道高反应性、神经和神经免疫系统疾病、神经病理性疼痛的急性和慢性疾病、炎性疼痛、自发性疼痛、阿片类诱导的疼痛、糖尿病性神经病、带状疱疹后神经痛、腰痛、化疗引起的神经病性疼痛、纤维肌痛、中枢神经系统的神经炎症和非神经炎症相关疾病、情绪障碍、重度抑郁症、抗抑郁症、双相情感障碍、焦虑性抑郁症、焦虑、认知、睡眠障碍、多发性硬化、癫痫发作、帕森病、精神分裂症、阿尔茨海默病、亨廷顿病、自闭症、脊髓损伤和脑缺血/颅脑损伤、与压力有关的疾病、心血管、代谢、胃肠和泌尿生殖系统疾病,如糖尿病、糖尿病、血栓形成、肠易激综合征、克罗恩病、缺血性心脏病、缺血、高血压、心血管疾病、心肌梗塞和下尿路功能障碍,如失禁、下尿路综合征、多囊肾病、肾小球肾炎、骨骼疾病、骨质疏松症、骨化不全症和青光眼、间质性膀胱炎、咳嗽、输尿管梗阻、败血症、肌萎缩性脊髓侧索硬化症、查加病、沙眼衣原体、神经母细胞瘤、结核和偏头痛。
  • Compounds targeting proteins, compositions, methods, and uses thereof
    申请人:BioTheryX, Inc.
    公开号:US10040804B2
    公开(公告)日:2018-08-07
    The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.
    本发明提供了调节蛋白质功能的化合物,以恢复蛋白质的平衡,包括细胞因子、CK1α、GSPT1、aiolos 和/或 ikaros 活性以及细胞-细胞粘附性。本发明提供了调节蛋白质介导的疾病,如细胞因子介导的疾病、失调、病症或反应的方法。本发明提供了组合物,包括与其他细胞因子和炎症介质的组合物。提供了治疗、改善或预防与蛋白质相关的疾病、失调或病症的方法,例如与细胞因子相关的疾病、失调和病症,包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、屑病、屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
  • Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
    申请人:MITSUI CHEMICALS AGRO, INC.
    公开号:US11178870B2
    公开(公告)日:2021-11-23
    Pyridine compounds of Formula (1) are provided: wherein R1, R2, X, Y and Het are defined. The pyridine compounds can be used to treat or prevent plant diseases.
    提供了式 (1) 的吡啶化合物: 其中 R1、R2、X、Y 和 Het 已定义。吡啶化合物可用于治疗或预防植物病害。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-